Pazopanib + Paclitaxel
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Angiosarcoma
Conditions
Angiosarcoma
Trial Timeline
Jul 1, 2014 → Jul 1, 2020
NCT ID
NCT02212015About Pazopanib + Paclitaxel
Pazopanib + Paclitaxel is a phase 2 stage product being developed by Novartis for Angiosarcoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02212015. Target conditions include Angiosarcoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02383251 | Phase 2 | Completed |
| NCT02212015 | Phase 2 | Terminated |
Competing Products
6 competing products in Angiosarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eribulin | Eisai | Phase 2 | 52 |
| Avelumab + Paclitaxel | Merck | Phase 2 | 52 |
| Pembrolizumab plus Lenvatinib | Merck | Phase 2 | 52 |
| regorafenib | Bayer | Phase 2 | 49 |
| Vusolimogene Oderparepvec (VO) + Pembrolizumab | Replimune | Phase 2 | 44 |
| AGEN2034 + AGEN1884 | Agenus | Phase 2 | 44 |